Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX - A Multicenter, FRENCH-PRODIGE Randomized Comparative Phase II/III Trial FRENCH26 - PRODIGE93 - PANACHE 02 Trial

NCT07044453 is registered in ClinicalTrials.gov with University Hospital, Rouen as lead sponsor.

NCT NCT07044453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07044453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX - A Multicenter, FRENCH-PRODIGE Randomized Comparative Phase II/III Trial FRENCH26 - PRODIGE93 - PANACHE 02 Trial
Lead sponsor
University Hospital, Rouen
Phase
Phase 2/3
Overall status
Recruiting
Start date
December 8, 2025
Completion date
September 30, 2032
Enrollment
390 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resected pancreatic adenocarcinoma